Short-term and long-term impact of COVID-19 on multiple sensory systems

COVID-19 对多种感觉系统的短期和长期影响

基本信息

  • 批准号:
    10564687
  • 负责人:
  • 金额:
    $ 51.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-02-01 至 2028-01-31
  • 项目状态:
    未结题

项目摘要

Project Summary Since its outbreak in China in December 2019, the global impact of SARS-CoV-2 infection has been extraordinary, with over 350 million cases and more than 5.5 million lives lost (WHO Coronavirus Dashboard, Jan 2022). Despite various public health measures, such as social distancing, handwashing, face masking, and vaccination, infections in the US and the world continue in waves driven by new variants of concern (WHO). While the pandemic landscape has been constantly shifting, epidemiologists and public health experts increasingly project that the virus could eventually become endemic, especially with emerging zoological reservoirs. While information is still emerging, the full picture of neurological consequences of COVID-19 to broad sensory functions remains unclear, especially in the context of new variants, vaccination, prior infection, and ongoing treatment. For example, smell loss has been a hallmark symptom of COVID-19 (>80%) and can present in isolation (the only symptom of COVID-19) or precede the occurrence of other symptoms. Epidemiology studies have shown that smell loss is the most predictive symptom for COVID-19, better in identifying COVID-19 patients than cough, fever, headache, or other typical symptoms used to screen for COVID-19 in workplaces, schools, and health care settings. But with the emergence of Delta and Omicron variants and vaccination, it is unclear whether olfaction function is still severely impacted as in the early stage of the pandemic. Similarly, taste and chemesthesis (trigeminal) losses have been implicated but not fully differentiated from the flavor loss caused by retronasal smell losses. Sudden onset of hearing loss and dizziness have also been self-reported among COVID-19 patients, but current evidence for these are still limited, despite being in the 3rd year of the pandemic. In this study, Aim 1 will apply multidisciplinary methodologies to extensively capture and quantify the full impact of COVID-19 on broad sensory functions (smell, taste, chemesthesis, hearing, balance/vestibular function), with endemic viral upper respiratory infection (URI: cold, flu, etc.) as a comparison group. These tests will allow us to extensively explore and differentiate the impact of COVID-19 on multiple sensory functions and their association with the disease profile, such as severity, dominant variant at the time of infection, vaccination status, prior infections, and treatment received, with potential to characterize common and distinct factors to that of URI. Aim 2 will broadly assess the longitudinal time course of sensory loss and recovery among COVID-19 patients, with the expectation that recovery can vary depending on the system affected and the disease profile. Aim 3 will specifically focus on COVID-19 “long haulers”, patients who have persistent symptoms (>90 days), to examine the different characteristics in sensory losses and recovery during the prolonged disease phase. The outcomes of this study could importantly expand our understanding of the characteristics of broad sensory losses and their recovery among COVID-19 patients.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KAI ZHAO其他文献

KAI ZHAO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KAI ZHAO', 18)}}的其他基金

Novel mechanisms and therapeutic approaches for nasal obstruction and olfactory losses
鼻塞和嗅觉丧失的新机制和治疗方法
  • 批准号:
    10587159
  • 财政年份:
    2022
  • 资助金额:
    $ 51.94万
  • 项目类别:
Novel mechanisms and therapeutic approaches for nasal obstruction and olfactory losses
鼻塞和嗅觉丧失的新机制和治疗方法
  • 批准号:
    10710211
  • 财政年份:
    2022
  • 资助金额:
    $ 51.94万
  • 项目类别:
Endoscopic nasal sinus surgery simulator to optimize treatment outcome
内窥镜鼻窦手术模拟器可优化治疗效果
  • 批准号:
    9884609
  • 财政年份:
    2019
  • 资助金额:
    $ 51.94万
  • 项目类别:
Objective evaluation of conductive olfactory losses & nasal obstruction symptoms
传导性嗅觉损失的客观评估
  • 批准号:
    8801195
  • 财政年份:
    2014
  • 资助金额:
    $ 51.94万
  • 项目类别:
Objective evaluation of conductive olfactory losses & nasal obstruction symptoms
传导性嗅觉损失的客观评估
  • 批准号:
    9185851
  • 财政年份:
    2014
  • 资助金额:
    $ 51.94万
  • 项目类别:
Objective evaluation of conductive olfactory losses & nasal obstruction symptoms
传导性嗅觉损失的客观评估
  • 批准号:
    9118609
  • 财政年份:
    2014
  • 资助金额:
    $ 51.94万
  • 项目类别:
Nasal airflow and odorant transport: a prerequisite for normal olfaction
鼻气流和气味输送:正常嗅觉的先决条件
  • 批准号:
    7213902
  • 财政年份:
    2006
  • 资助金额:
    $ 51.94万
  • 项目类别:
Nasal airflow and odorant transport: a prerequisite for normal olfaction
鼻气流和气味输送:正常嗅觉的先决条件
  • 批准号:
    7326769
  • 财政年份:
    2006
  • 资助金额:
    $ 51.94万
  • 项目类别:
Nasal airflow and odorant transport: a prerequisite for normal olfaction
鼻气流和气味输送:正常嗅觉的先决条件
  • 批准号:
    7533479
  • 财政年份:
    2006
  • 资助金额:
    $ 51.94万
  • 项目类别:

相似国自然基金

新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介 导“肠-胰岛 ”轴血糖调控功能的降糖机制研 究
  • 批准号:
    Y24H280055
  • 批准年份:
    2024
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
  • 批准号:
    82330111
  • 批准年份:
    2023
  • 资助金额:
    220 万元
  • 项目类别:
    重点项目
CAFs来源的外泌体负性调控ACE2促进肾透明细胞癌癌栓新辅助靶向耐药的机制研究
  • 批准号:
    82373169
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
新型蝙蝠MERS簇冠状病毒HKU5的ACE2受体识别及细胞入侵机制研究
  • 批准号:
    32300137
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
基于外泌体miRNAs介导细胞通讯的大豆ACE2激活肽调控血管稳态机制研究
  • 批准号:
    32302080
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
感毒清经ACE2/Ang(1-7)/MasR信号通路抑制PM2.5诱导慢性气道炎症的机制:聚焦肺泡巨噬细胞极化与“胞葬”的表型串扰
  • 批准号:
    82305171
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
刺参自溶引发机制中ACE2调控靶点的调控网络研究
  • 批准号:
    32372399
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
Spike变异对新冠病毒抗原性及ACE2种属嗜性的影响研究
  • 批准号:
    82272305
  • 批准年份:
    2022
  • 资助金额:
    52 万元
  • 项目类别:
    面上项目

相似海外基金

新型コロナウイルス感染阻害能を有する抗ACE2抗体の阻害機構に関する構造基盤解明
阐明具有抑制新型冠状病毒感染能力的抗ACE2抗体抑制机制的结构基础
  • 批准号:
    24K09338
  • 财政年份:
    2024
  • 资助金额:
    $ 51.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
ACE2のユビキチン化を介したコロナウイルス感染機構の解明と創薬への挑戦
通过ACE2泛素化阐明冠状病毒感染机制和药物发现的挑战
  • 批准号:
    22KJ2499
  • 财政年份:
    2023
  • 资助金额:
    $ 51.94万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
ACE2阻害薬およびERK経路阻害薬による慢性腎炎進展抑制効果の検証
ACE2抑制剂和ERK通路抑制剂抑制慢性肾炎进展的效果验证
  • 批准号:
    23K14982
  • 财政年份:
    2023
  • 资助金额:
    $ 51.94万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Large-scale compatibility assessments between ACE2 proteins and diverse sarbecovirus spikes
ACE2 蛋白和多种 sarbecovirus 尖峰之间的大规模兼容性评估
  • 批准号:
    10722852
  • 财政年份:
    2023
  • 资助金额:
    $ 51.94万
  • 项目类别:
一次線毛とコロナウイルス感染におけるACE2の役割の解明
阐明 ACE2 在原发菌毛和冠状病毒感染中的作用
  • 批准号:
    22KF0004
  • 财政年份:
    2023
  • 资助金额:
    $ 51.94万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
The regulatory roles of ACE2 and its interaction with Nrf2 in arsenic-induced endothelial dysfunction in experimental and epidemiological studies
实验和流行病学研究中 ACE2 的调节作用及其与 Nrf2 的相互作用在砷诱导的内皮功能障碍中的作用
  • 批准号:
    23K16310
  • 财政年份:
    2023
  • 资助金额:
    $ 51.94万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Role of ACE2 in the mechanism of intestinal regeneration
ACE2在肠道再生机制中的作用
  • 批准号:
    23K15078
  • 财政年份:
    2023
  • 资助金额:
    $ 51.94万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Research and development of a novel pediatric anti-obesity medicine via ACE2 activation in DIZE
通过 DIZE 中 ACE2 激活研发新型儿科抗肥胖药物
  • 批准号:
    23K15417
  • 财政年份:
    2023
  • 资助金额:
    $ 51.94万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Lung delivery of novel ACE2 variants for COVID-19
针对 COVID-19 的新型 ACE2 变体的肺部输送
  • 批准号:
    10483042
  • 财政年份:
    2022
  • 资助金额:
    $ 51.94万
  • 项目类别:
ACE2 on gut barrier dysfunction and BRB disruption
ACE2 对肠道屏障功能障碍和 BRB 破坏的影响
  • 批准号:
    10535485
  • 财政年份:
    2022
  • 资助金额:
    $ 51.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了